Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Medtronic PLC    MDT   IE00BTN1Y115

News SummaryMost relevantAll newsSector newsTweets

Medtronic (SWX:MDT) Kicks Off CoreValve Evolut Pro Valve Evaluation

share with twitter share with LinkedIn share with facebook
share via e-mail
09/29/2017 | 12:53pm CEST

Medtronic (SWX:MDT) has announced that it has initiated a post market clinical evaluation of its CoreValve Evolut Pro valve.

The newly announced clinical study of the CoreValve Evolut Pro valve will evaluate its performance based on day to day clinical use. The clinical study will also involve the participation of patients suffering from severe symptomatic aortic stenosis especially those that have a moderate or severe risk of open heart surgery. The evaluation will determine the performance for a duration of five years as it ushers in the future self-expanding TAVI system which recently received approval for use in the U.S and Europe.

“We look forward to replicating the excellent clinical outcomes demonstrated by the Evolut Pro valve in a study designed to look at the valve’s longer-term real-world performance. The Evolut PRO has shown exceptional results for patients with severe aortic stenosis and we are excited to enroll our first patients into this rigorous study,” stated Dr. Eberhard Grube of Bonn, the co-principal investigator for the clinical study.

The evaluation will be a single-arm study that will involve multiple centers. It also aims to involve 600 patients from 35 European locations in determining the safety of the offering. The CoreValve Evolut Pro consists of an outer wrap that contributes to the surface area between the native aortic annulus and the valve in order to boost the valve sealing performance. The company also revealed that the device features a small form factor to allow for easy delivery through the EnVeo R delivery catheter system.

Dr. Pieter Kappetein, the president of structural heart biz medical affairs at Medtronic pointed a few critical points during a press release. He highlighted that it is his company’s agenda to continue pushing towards meaningful clinical outcomes that are vital for patients as new products enter the global transcatheter valve market. He also added that the outcomes also have to resonate with the physicians and that the company is optimistic that the enhancements featured in the self-expanding Evolut TAVI platform will facilitate better outcomes for patients. Medtronic also hopes that the study will contribute provide evidence of long-term safety and performance.


The post Medtronic (SWX:MDT) Kicks Off CoreValve Evolut Pro Valve Evaluation appeared first on Market Exclusive.

© Market Exclusive 2017, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MEDTRONIC PLC
10/18 MEDTRONIC : Prosthetics-Portland - MEDTRONIC - Pre Urgent 648Q82288
10/18 MEDTRONIC : 65-- Prosthetics-Portland - MEDTRONIC - Pre Urgent 648Q82288
10/18 MEDTRONIC : Care Management Services and American Well Announce Strategic Partne..
10/17 MEDTRONIC : Care Management Services, American Well Announce Strategic Partnersh..
10/17 MEDTRONIC : Care Management Services and American Well Announce Strategic Partne..
10/17 MEDTRONIC : and Mercy Announce Data Sharing Partnership to Accelerate Medical De..
10/16 MEDTRONIC : Care Management Services and American Well Announce Strategic Partne..
10/13 MEDTRONIC : Prosthetics-Seattle (Medtronic) Pay Only DOS 09/18/17 (VA-18-919420)..
10/13 MEDTRONIC : 65-- Prosthetics-Seattle (Medtronic) Pay Only DOS 09/18/17 (VA-18-91..
10/13 65-- RFI MEDTRONIC - NX EQ RADIO FRE : Tissue Ablation Program;
More news
News from SeekingAlpha
10/17 YOUR DAILY PHARMA SCOOP : Everybody's Gilead Problem, Halozyme's Further Progres..
10/12 Wright Can't Get It Right
10/12 My Dividend Growth Portfolio - Q3 2017 Summary
10/12 The Lower Volatility Stock Portfolio For Retirees And Others
10/10 YOUR DAILY PHARMA SCOOP : MannKind Is A Trade Not An Investment; AstraZeneca's I..
Financials ($)
Sales 2018 29 262 M
EBIT 2018 8 299 M
Net income 2018 4 607 M
Debt 2018 16 892 M
Yield 2018 2,35%
P/E ratio 2018 23,96
P/E ratio 2019 20,36
EV / Sales 2018 4,22x
EV / Sales 2019 3,98x
Capitalization 106 B
Duration : Period :
Medtronic PLC Technical Analysis Chart | MDT | IE00BTN1Y115 | 4-Traders
Technical analysis trends MEDTRONIC PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 90,0 $
Spread / Average Target 14%
EPS Revisions
Omar S. Ishrak Chairman & Chief Executive Officer
Mark Ploof Senior Vice President-Global Operations
Karen L. Parkhill Chief Financial Officer & Executive Vice President
Richard E. Kuntz Chief Scientific, Clinical & Regulatory Officer
Richard H. Anderson Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC10.33%106 457
C R BARD INC45.55%23 764
TERUMO CORP8.55%15 770